Tota l Syn th esis of th e Eigh t Dia ster eom er s of th e Syn -An ti-Syn
P h ytop r osta n es F 1 Typ es I a n d II
Siham El Fangour, Alexandre Guy, Vale´rie Despres, J ean-Pierre Vidal,
J ean-Claude Rossi, and Thierry Durand*
UMR CNRS 5074, Universite´ Montpellier I, Faculte´ de Pharmacie, 3e Etage-15, Avenue Charles Flahault,
F-34093 Montpellier Cedex 05, France
thierry.durand@univ-montp1.fr
Received November 7, 2003
Syntheses of the eight enantiomerically pure diastereomers of the syn-anti-syn phytoprostanes F1
types I and II are described starting from D- and L-glucose. Key steps include Wittig coupling,
Horner Wadsworth Emmons (HWE) reactions, and enantioselective reduction of R,â-unsaturated
ketones.
In tr od u ction
the syntheses of all eight diastereomers of the syn-anti-
syn PPF1 types I and II starting from cyclopentane
precursors 3 and 3′, obtained from D- and L-glucose
(Scheme 1).
Isoprostanes (IsoPs) represent a new family of bio-
markers for oxidative stress generated from peroxidation
of polyunsaturated fatty acids via a free-radical-catalyzed
mechanism.1,2 Higher plants generally do not synthesize
the arachidonate precursor required for isoPs formation,
but rather utilize R-linolenic acid for the formation of
isoprostane F2-like compounds which have been termed
phytoprostanes F1 (PPF1).3 J asmonates are established
plant signaling compounds inducing defense responses.4
Preliminary data indicate that phytoprostanes also in-
duce phytoalexins in a variety of plant species, suggesting
a possible function of phytoprostanes as mediators of
plant defense reactions in response to oxidative stress.5,6
Since we were interested in assessing the physiological
activities of each of the phytoprostanes F1 types I and
II, we found it more attractive to obtain sufficient
quantities by chemical synthesis.
Resu lts a n d Discu ssion
The Phytoprostanes F1 types I and II were identified
from autoxidation of R-linolenic acid by Mueller.3 To
confirm the stereochemistry of the eight enantiomerically
pure diastereomers of phytoprostanes F1 types I and II,
and also to screen the physiological activity of these
phytoprostanes, we have developed a general and flexible
strategy from our common intermediate syn-anti-syn
cyclopentane precursors 3 and 3′ (Scheme 1).
Syn th esis of en t-P h ytop r osta n e F 1 Typ e I 1 a n d
2 fr om D-Glu cose. The syntheses of ent-PPF1 type I 1
and its 16(S) epimer 2 from the cyclopentane percursor
3 is shown in Schemes 2-4 and was published as a note.7
The first 9 steps leading to cyclopentane alkoxyester 3
were achieved in 27% overall yield by using our iodo
pathway.8
In 2003, we published a note describing the syntheses
of ent-PPF1 type I 1 and its 16-epimer 2.7 We now report
The phosphorus synthon 7 was selected for the intro-
duction of the upper chain of the PPF1 type I, and was
prepared by using the procedure outlined in Scheme 2.
The first step is the opening of the ꢀ-caprolactone under
acidic conditions leading to the corresponding hydroxy
methyl ester 5. Subsequent halogenation gave iodo ester
6, which was transformed into the phophonium salt 7 in
98% yield in the presence of PPh3 and a catalytic amount
of K2CO3.
* Address correspondence to this author. Phone: 33-4-67-54-86-23.
Fax: 33-4-67-54-86-25.
(1) (a) Morrow, J . D.; Hill, K. E.; Burk, R. F.; Nammour, T. M.; Badr,
K. F.; Roberts, L. J ., II Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9383-
9387. (b) Nourooz-Zadeh, J .; Liu, E. H. C.; Anggard, E. E.; Halliwell,
B. Biochem. Biophys. Res. Commun. 1998, 242, 338-344. (c) Roberts,
L. J ., II; Montine, T. J .; Markesbery, W. R.; Tapper A. R.; Hardy, P.;
Chemtob, S.; Dettbarn, W. D.; Morrow, J . D. J . Biol. Chem. 1998, 273,
13605-13612. (d) Nourooz-Zadeh, J .; Liu, E. H. C.; Yhlen, B.; A¨ nggard,
E. E.; Halliwell, B. J . Neurochem. 1999, 72, 734-740.
(2) (a) Roberts, L. J ., II; Morrow J . D. Free Radical Biol. Med. 2000,
28, 505-513. (b) Cracowski, J . L.; Durand, T.; Bessard, G. Trends
Pharmacol. Sci. 2002, 23, 360-366.
The introduction of the upper chain (Scheme 3) was
achieved by using the above phosphonium salt 7, which
(3) Imbusch, R.; Mueller, M. J . Plant Physiol. 2000, 124, 1293-
12303.
(4) Stintzi, A.; Weber, H.; Reymond, P.; Browse, J .; Farmer, E. E.
Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 12837-12842.
(5) Imbusch, R.; Mueller, M. J . Free Radical Biol. Med. 2000, 28,
720-726.
(6) Thoma, I.; Loeffler, C.; Sinha, A. K.; Gupta, M.; Krischke, M.;
Steffan, B.; Roitsch, T.; Mueller, M. J . Plant J . 2003, 34 (3), 363-375.
(7) El Fangour, S.; Guy, A.; Vidal, J .-P.; Rossi, J .-C.; Durand, T.
Tetrahedron Lett. 2003, 44, 2105-2108.
(8) Durand, T.; Guy, A.; Henry, O.; Vidal, J . P.; Rossi, J . C. Eur. J .
Org. Chem. 2001, 4, 809-819 and references therein.
10.1021/jo035638i CCC: $27.50 © 2004 American Chemical Society
Published on Web 03/05/2004
2498
J . Org. Chem. 2004, 69, 2498-2503